Back to search
FDAFDA · Food and drugs·Recall number D-0626-2024

Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles.

Published August 14, 2024 · Recall initiated: July 18, 2024

Summary

FDA records drug Class I recall D-0626-2024, published August 14, 2024 and initiated July 18, 2024. Recalling firm: MAIN PRODUCTS INC; Status: Ongoing; Reported quantity: 57, 340 bottles; Lot: All lots within expiry. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed without Approved NDA/ANDA. FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
MAIN PRODUCTS INC
Distributor
Nationwide within the U.S
Lot
All lots within expiry
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles. recalled?

Yes. FDA published recall D-0626-2024 on August 14, 2024. Reported hazard: Marketed without Approved NDA/ANDA. FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.

What should I do if I have this product?

Voluntary: Firm initiated · Letter